MicroRNAs as potential diagnostic biomarkers for bipolar disorder

Bridget Martinez, P. Peplow
{"title":"MicroRNAs as potential diagnostic biomarkers for bipolar disorder","authors":"Bridget Martinez, P. Peplow","doi":"10.4103/nrr.nrr-d-23-01588","DOIUrl":null,"url":null,"abstract":"\n Abnormal expression of microRNAs is connected to brain development and disease and could provide novel biomarkers for the diagnosis and prognosis of bipolar disorder. We performed a PubMed search for microRNA biomarkers in bipolar disorder and found 18 original research articles on studies performed with human patients and published from January 2011 to June 2023. These studies included microRNA profiling in blood-and brain-based materials. From the studies that had validated the preliminary findings, potential candidate biomarkers for bipolar disorder in adults could be miR-140-3p, -30d- 5p, -330-5p, -378a-5p, -21-3p, -330-3p, -345-5p in whole blood, miR-19b-3p, -1180-3p, -125a-5p, let-7e-5p in blood plasma, and miR-7-5p, -23b-5p, -142-3p, -221-5p, -370-3p in the blood serum. Two of the studies had investigated the changes in microRNA expression of patients with bipolar disorder receiving treatment. One showed a significant increase in plasma miR-134 compared to baseline after 4 weeks of treatment which included typical antipsychotics, atypical antipsychotics, and benzodiazepines. The other study had assessed the effects of prescribed medications which included neurotransmitter receptor-site binders (drug class B) and sedatives, hypnotics, anticonvulsants, and analgesics (drug class C) on microRNA results. The combined effects of the two drug classes increased the significance of the results for miR-219 and -29c with miR-30e-3p and -526b* acquiring significance. MicroRNAs were tested to see if they could serve as biomarkers of bipolar disorder at different clinical states of mania, depression, and euthymia. One study showed that upregulation in whole blood of miR-9-5p, -29a-3p, -106a-5p, -106b-5p, -107, -125a-3p, -125b-5p and of miR-107, -125a-3p occurred in manic and euthymic patients compared to controls, respectively, and that upregulation of miR-106a-5p, -107 was found for manic compared to euthymic patients. In two other studies using blood plasma, downregulation of miR-134 was observed in manic patients compared to controls, and dysregulation of miR-134, -152, -607, -633, -652. -155 occurred in euthymic patients compared to controls. Finally, microRNAs such as miR-34a, -34b, -34c, -137 and -140- 3p, -21-3p, -30d-5p, -330-5p, -378a-5p, -134, -19b-3p were shown to have diagnostic potential in distinguishing bipolar disorder patients from schizophrenia or major depressive disorder patients, respectively. Further studies are warranted with adolescents and young adults having bipolar disorder and consideration should be given to using animal models of the disorder to investigate the effects of suppressing or overexpressing specific microRNAs.","PeriodicalId":506566,"journal":{"name":"Neural Regeneration Research","volume":"11 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neural Regeneration Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/nrr.nrr-d-23-01588","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Abnormal expression of microRNAs is connected to brain development and disease and could provide novel biomarkers for the diagnosis and prognosis of bipolar disorder. We performed a PubMed search for microRNA biomarkers in bipolar disorder and found 18 original research articles on studies performed with human patients and published from January 2011 to June 2023. These studies included microRNA profiling in blood-and brain-based materials. From the studies that had validated the preliminary findings, potential candidate biomarkers for bipolar disorder in adults could be miR-140-3p, -30d- 5p, -330-5p, -378a-5p, -21-3p, -330-3p, -345-5p in whole blood, miR-19b-3p, -1180-3p, -125a-5p, let-7e-5p in blood plasma, and miR-7-5p, -23b-5p, -142-3p, -221-5p, -370-3p in the blood serum. Two of the studies had investigated the changes in microRNA expression of patients with bipolar disorder receiving treatment. One showed a significant increase in plasma miR-134 compared to baseline after 4 weeks of treatment which included typical antipsychotics, atypical antipsychotics, and benzodiazepines. The other study had assessed the effects of prescribed medications which included neurotransmitter receptor-site binders (drug class B) and sedatives, hypnotics, anticonvulsants, and analgesics (drug class C) on microRNA results. The combined effects of the two drug classes increased the significance of the results for miR-219 and -29c with miR-30e-3p and -526b* acquiring significance. MicroRNAs were tested to see if they could serve as biomarkers of bipolar disorder at different clinical states of mania, depression, and euthymia. One study showed that upregulation in whole blood of miR-9-5p, -29a-3p, -106a-5p, -106b-5p, -107, -125a-3p, -125b-5p and of miR-107, -125a-3p occurred in manic and euthymic patients compared to controls, respectively, and that upregulation of miR-106a-5p, -107 was found for manic compared to euthymic patients. In two other studies using blood plasma, downregulation of miR-134 was observed in manic patients compared to controls, and dysregulation of miR-134, -152, -607, -633, -652. -155 occurred in euthymic patients compared to controls. Finally, microRNAs such as miR-34a, -34b, -34c, -137 and -140- 3p, -21-3p, -30d-5p, -330-5p, -378a-5p, -134, -19b-3p were shown to have diagnostic potential in distinguishing bipolar disorder patients from schizophrenia or major depressive disorder patients, respectively. Further studies are warranted with adolescents and young adults having bipolar disorder and consideration should be given to using animal models of the disorder to investigate the effects of suppressing or overexpressing specific microRNAs.
作为双相情感障碍潜在诊断生物标志物的微量核糖核酸
微RNA的异常表达与大脑发育和疾病有关,可为双相情感障碍的诊断和预后提供新的生物标志物。我们在PubMed上搜索了双相情感障碍的microRNA生物标志物,发现了18篇原始研究文章,这些文章是以人类患者为研究对象,发表于2011年1月至2023年6月。这些研究包括血液和脑部材料中的 microRNA 分析。从验证了初步发现的研究中,成人躁郁症的潜在候选生物标志物可能是 miR-140-3p、-30d- 5p、-330-5p、-378a-5p、-血浆中的 miR-19b-3p、-1180-3p、-125a-5p、let-7e-5p,以及血清中的 miR-7-5p、-23b-5p、-142-3p、-221-5p、-370-3p。其中两项研究调查了接受治疗的双相情感障碍患者体内 microRNA 表达的变化。其中一项研究显示,经过4周的治疗(包括典型抗精神病药物、非典型抗精神病药物和苯二氮卓类药物)后,血浆中的miR-134与基线相比明显增加。另一项研究评估了处方药(包括神经递质受体位点结合剂(B 类药物)和镇静剂、催眠药、抗惊厥药和镇痛药(C 类药物))对 microRNA 结果的影响。两类药物的共同作用增加了 miR-219 和 -29c 结果的显著性,miR-30e-3p 和 -526b* 获得了显著性。研究人员对微小核糖核酸进行了测试,以确定它们是否可以作为双相情感障碍在躁狂、抑郁和健康状态等不同临床状态下的生物标志物。一项研究显示,与对照组相比,躁狂症患者和抑郁症患者的全血中 miR-9-5p、-29a-3p、-106a-5p、-106b-5p、-107、-125a-3p、-125b-5p 以及 miR-107、-125a-3p 出现了上调;与抑郁症患者相比,躁狂症患者的 miR-106a-5p、-107 出现了上调。在另外两项使用血浆的研究中,与对照组相比,躁狂症患者的 miR-134 出现下调,而躁狂症患者的 miR-134、-152、-607、-633、-652 和-155 则出现失调。与对照组相比,躁狂症患者的 miR-134、-152、-607、-633、-652、-155 均出现失调。最后,miR-34a、-34b、-34c、-137 和 -140- 3p、-21-3p、-30d-5p、-330-5p、-378a-5p、-134、-19b-3p 等 microRNAs 被证明在区分双相情感障碍患者与精神分裂症或重度抑郁症患者方面分别具有诊断潜力。有必要对患有双相情感障碍的青少年进行进一步研究,并应考虑使用该障碍的动物模型来研究抑制或过度表达特定 microRNA 的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信